Extracellular matrix modulates beta2-adrenergic receptor signaling in human airway smooth muscle cells.
The airways of patients with chronic asthma commonly develop an element of fixed airway obstruction, which fails to reverse with inhaled beta2-adrenoceptor agonists. Airway remodeling refers to the structural changes of the bronchi in longstanding asthma and is characterized by increased deposition and altered ratios of extracellular matrix (ECM) proteins. We therefore assessed whether ECM proteins alter beta2-adrenoceptor signaling in human airway smooth muscle cells. We report that a fibronectin environment increases responses to beta2-adrenoceptor stimulation, whereas exposure to collagen V or laminin decreases accumulation of the second messenger cyclic AMP when compared with collagens I or IV. These differences are likely to be physiologically significant as they translate into altered phosphorylation of the downstream target VASP. The altered cAMP levels are due to differences in adenylyl cyclase activity, although expression of the relevant isoforms of enzyme appears unaltered. However, inhibition of Galphai abrogates the differences in beta2-adrenoceptor-mediated cAMP accumulation in cells exposed to different matrix factors. The difference in Galphai signaling is not due to altered Galphai expression. We conclude therefore that ECM modulates Galphai activity in human airway smooth muscle cells, and propose that these changes could contribute to the fixed airway obstruction seen in patients with chronic asthma.
Freyer
Anette M
AM
Division of Therapeutics and Molecular Biology, University of Nottingham, D Floor, South Block, Queens Medical Centre, Nottingham NG7 2UH, UK. anette.freyer@nottingham.ac.uk
Billington
Charlotte K
CK
Penn
Raymond B
RB
Hall
Ian P
IP
D000262:Adenylyl Cyclases / Q000378:metabolism; D000402:Airway Obstruction / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D018927:Anti-Asthmatic Agents / Q000494:pharmacology; D001249:Asthma / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D015815:Cell Adhesion Molecules / Q000378:metabolism; D024062:Collagen Type V / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D005109:Extracellular Matrix / Q000187:drug effects / Q000502:physiology*; D016326:Extracellular Matrix Proteins / Q000378:metabolism; D005353:Fibronectins / Q000494:pharmacology; D051960:GTP-Binding Protein alpha Subunit, Gi2; D019206:GTP-Binding Protein alpha Subunits, Gi-Go / Q000378:metabolism; D006801:Humans; D007797:Laminin / Q000494:pharmacology; D008840:Microfilament Proteins; D032389:Myocytes, Smooth Muscle / Q000187:drug effects / Q000378:metabolism*; D010750:Phosphoproteins / Q000378:metabolism; D010766:Phosphorylation; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D018343:Receptors, Adrenergic, beta-2 / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D014132:Trachea / Q000737:chemistry; D000098662:Vasodilator-Stimulated Phosphoprotein
D018927:Anti-Asthmatic Agents; D015815:Cell Adhesion Molecules; D024062:Collagen Type V; D016326:Extracellular Matrix Proteins; D005353:Fibronectins; D007797:Laminin; D008840:Microfilament Proteins; D010750:Phosphoproteins; D011518:Proto-Oncogene Proteins; D018343:Receptors, Adrenergic, beta-2; D000098662:Vasodilator-Stimulated Phosphoprotein; D000242:Cyclic AMP; C498015:GNAI2 protein, human; C498819:GNAI3 protein, human; D051960:GTP-Binding Protein alpha Subunit, Gi2; D019206:GTP-Binding Protein alpha Subunits, Gi-Go; D000262:Adenylyl Cyclases